95 related articles for article (PubMed ID: 11064911)
1. [Free PSA: its routine use is premature in the screening of prostatic cancer].
Villers A; Chautard D
Prog Urol; 2000 Sep; 10(4):618-21. PubMed ID: 11064911
[TBL] [Abstract][Full Text] [Related]
2. [Is it possible to define a threshold for free PSA index that is useful in the daily practice of urology?].
Chautard D; Bocquillon V; Daver A; Colls P; Soret JY
Prog Urol; 2000 Sep; 10(4):571-7. PubMed ID: 11064899
[TBL] [Abstract][Full Text] [Related]
3. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
4. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Gann PH; Ma J; Catalona WJ; Stampfer MJ
J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
[TBL] [Abstract][Full Text] [Related]
5. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
[TBL] [Abstract][Full Text] [Related]
6. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
7. Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
[TBL] [Abstract][Full Text] [Related]
8. Receiver operating characteristics of the prostate specific antigen test in an unselected population.
McLernon DJ; Donnan PT; Gray M; Weller D; Sullivan F
J Med Screen; 2006; 13(2):102-7. PubMed ID: 16792835
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
[TBL] [Abstract][Full Text] [Related]
10. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
11. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
12. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
13. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
15. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
Rowe EW; Laniado ME; Walker MM; Patel A
BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
19. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
20. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
